Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 45/100

Failure Rate

0.0%

0 terminated/withdrawn out of 6 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

0 trials in Phase 3/4

Results Transparency

0 of 4 completed trials have results

Key Signals

2 recruiting

Enrollment Performance

Analytics

N/A

2(66.7%)

Phase 2

1(33.3%)

3Total

N/A(2)

Phase 2(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (6)

Showing 6 of 6 trials

NCT03926520Not ApplicableRecruiting

Electroconvulsive Therapy (ECT) for Agitation in Dementia (AD)

Role: collaborator

NCT06529029Phase 2Recruiting

Low Amplitude Pulse Seizure Therapy Versus Standard Ultra-Brief Right Unilateral Electroconvulsive Therapy

Role: collaborator

NCT04159207Completed

A Longitudinal Study of Inflammatory Pathways in Depression

Role: collaborator

NCT02566980Completed

Biological Triggers of Depression in Pregnancy

Role: collaborator

NCT01261364Not ApplicableCompleted

Pharmacogenetic-Directed Treatment for Major Depression

Role: collaborator

NCT01856010Completed

Study of Electroconvulsive Therapy (ECT) Treatment for Agitation and Aggression in Dementia

Role: lead

All 6 trials loaded